Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was observed with ...
Spravato is just the beginning in a new wave of depression meds
When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.